Searchable abstracts of presentations at key conferences in endocrinology

ea0059p065 | Clinical biochemistry | SFEBES2018

An oestrogen profiling mass spectrometry method using N-Methyl Pyridine-3-sulfonyl chloride derivatisation

Johal Jamine , Jolly George , Gilligan Lorna C , Taylor Angela E

Objectives: Oestrogen analysis using liquid chromatography mass spectrometry is problematic, as oestrogens do not readily ionise. This coupled with low concentrations in men, pre-pubertal and post-menopausal women provides an analytical challenge. We investigated N-Methyl Pyridine-3-sulfonyl chloride (NMPS) derivatisation, as described by Wang et al. (Steroids 2015 Apr;96:140-152) to improve sensitivity of 11 oestrogens; oestrone (E1), oestradiol (E2), 2-hydroxy-oestr...

ea0050oc4.6 | Adrenal and Steroids | SFEBES2017

Distinct patterns of glucocorticoid metabolism in patients with HNF1A-MODY have the potential to confer a beneficial metabolic phenotype

Juszczak Agata , Gilligan Lorna C. , Hughes Beverly A. , Hassan-Smith Zaki K. , Arlt Wiebke , McCarthy Mark I. , Tomlinson Jeremy W. , Owen Katharine R.

Background and aims: HNF1A-MODY causes monogenic diabetes with a lean, insulin sensitive phenotype. Altered glucocorticoid (GC) metabolism has been implicated in the pathogenesis of type 2 diabetes (T2D) and inhibitors of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) which regenerates active cortisol from inactive cortisone have been trialled as a therapeutic approach. 11β-HSD1 is down-regulated in hepatocytes from Hnf1a knock-out mice but the role...

ea0050oc4.6 | Adrenal and Steroids | SFEBES2017

Distinct patterns of glucocorticoid metabolism in patients with HNF1A-MODY have the potential to confer a beneficial metabolic phenotype

Juszczak Agata , Gilligan Lorna C. , Hughes Beverly A. , Hassan-Smith Zaki K. , Arlt Wiebke , McCarthy Mark I. , Tomlinson Jeremy W. , Owen Katharine R.

Background and aims: HNF1A-MODY causes monogenic diabetes with a lean, insulin sensitive phenotype. Altered glucocorticoid (GC) metabolism has been implicated in the pathogenesis of type 2 diabetes (T2D) and inhibitors of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) which regenerates active cortisol from inactive cortisone have been trialled as a therapeutic approach. 11β-HSD1 is down-regulated in hepatocytes from Hnf1a knock-out mice but the role...

ea0059oc5.2 | Adrenal | SFEBES2018

Residual adrenal function in autoimmune addison s disease effect of dual therapy with rituximab and depot tetracosactide

Napier Catherine , Gan Earn H , Mitchell Anna L , Gilligan Lorna C , Rees Aled , Moran Carla , Chatterjee Krishna , Vaidya Bijay , Arlt Wiebke , Pearce Simon HS

In patients with autoimmune Addison’s disease (AAD), exogenous glucocorticoid (GC) therapy is an imperfect substitute for physiological GC secretion; patients on long-term steroid replacement have increased morbidity, reduced life expectancy and poorer quality of life. Recent early-phase studieshave demonstrated that some endogenous steroidogenic function – Residual Adrenal Function (RAF) - is maintained at the point of diagnosis in a proportion of AAD patients; this...

ea0077p42 | Metabolism, Obesity and Diabetes | SFEBES2021

Chronic inflammation regulates androgen metabolism and exposure in Macrophages

Martin Claire S , Kalirai Matthew Singh , Crastin Ana , Turner Jason D , Schiffer Lina , Gilligan Lorna C , Taylor Angela E , Scheel-Toellner Dagmar , Raza Karim , Filer Andrew , Jones Simon W , Arlt Wiebke , Hewison Martin , Hardy Rowan S

Active androgens exert immunomodulatory actions at sites of inflammation and lower levels are implicated in the increased incidence of rheumatoid arthritis (RA) in females. However, inflammatory regulation of intracrine androgen metabolism within cell populations at sites of inflammation remain poorly defined. In this study we characterised immune and stromal cell androgen metabolism in RA patients and assessed their functional significance. Using the online Accelerating Medic...

ea0065oc1.1 | Metabolism and Obesity | SFEBES2019

Intracrine activation of 11-oxygenated androgens by AKR1C3 modulates lipid metabolism in human female adipose tissue

Schiffer Lina , Sinclair Alexandra J , O'Reilly Michael W , Westgate Connar , Mashood Afeefa , Palmer Elliot , Gilligan Lorna C , Singhal Rishi , Taylor Angela E , Dunn Warwick B , Arlt Wiebke , Storbeck Karl-Heinz

Polycystic ovary syndrome (PCOS) affects 10% of women and is associated with an increased risk of type 2 diabetes and fatty liver disease. Androgen excess is an important driver of metabolic risk in PCOS. In adipose tissue from women with PCOS, increased activation of androstenedione (A4) to testosterone (T) by the enzyme AKR1C3 results in systemic lipotoxicity. Recent in-vitro studies also demonstrated that T and 11-ketotestosterone (11KT) activate the androgen recep...

ea0050oc2.1 | Clinical Highlights | SFEBES2017

Mild autonomous cortisol excess in adrenal incidentalomas – metabolic disease burden and urinary steroid metabolome in 1201 prospectively recruited patients

Prete Alessandro , Taylor Angela E , Sitch Alice J , Gilligan Lorna C , Vassiliadi Dimitra , Ambroziak Urzula , Lang Katharina , Kastelan Darko , Tabarin Antoine , Dennedy M Conall , Ueland Grethe AEstrom , Quinkler Marcus , Masjkur Jimmy Rusdian , Fassnacht Martin , Ivovic Miomira , Terzolo Massimo , Beuschlein Felix , Manolopoulos Konstantinos , Tsagarakis Stylianos , Shackleton Cedric H L , Deeks Jonathan J , Bancos Irina , Arlt Wiebke

Background: Adrenal incidentalomas (AI) are found in approximately 5% of the adult population. Most AIs are benign; however, small-scale studies have indicated that 20–50% of patients harbouring a benign AI show biochemical evidence of mild autonomous cortisol excess (MACE), previously termed subclinical Cushing’s syndrome. MACE is differentiated into MACE-1 (serum cortisol after overnight suppression with 1 mg dexamethasone (1 mg-DST) 50–140 nmol/l) and MACE-2 ...

ea0050oc2.1 | Clinical Highlights | SFEBES2017

Mild autonomous cortisol excess in adrenal incidentalomas – metabolic disease burden and urinary steroid metabolome in 1201 prospectively recruited patients

Prete Alessandro , Taylor Angela E , Sitch Alice J , Gilligan Lorna C , Vassiliadi Dimitra , Ambroziak Urzula , Lang Katharina , Kastelan Darko , Tabarin Antoine , Dennedy M Conall , Ueland Grethe AEstrom , Quinkler Marcus , Masjkur Jimmy Rusdian , Fassnacht Martin , Ivovic Miomira , Terzolo Massimo , Beuschlein Felix , Manolopoulos Konstantinos , Tsagarakis Stylianos , Shackleton Cedric H L , Deeks Jonathan J , Bancos Irina , Arlt Wiebke

Background: Adrenal incidentalomas (AI) are found in approximately 5% of the adult population. Most AIs are benign; however, small-scale studies have indicated that 20–50% of patients harbouring a benign AI show biochemical evidence of mild autonomous cortisol excess (MACE), previously termed subclinical Cushing’s syndrome. MACE is differentiated into MACE-1 (serum cortisol after overnight suppression with 1 mg dexamethasone (1 mg-DST) 50–140 nmol/l) and MACE-2 ...

ea0065ec1.3 | Clinical Endocrinology Trust Best Abstract Clinical | SFEBES2019

Urine steroid metabolome analysis allows for metabolic risk stratification in 1309 prospectively recruited patients with benign adrenal tumours and different degrees of cortisol excess

Prete Alessandro , Taylor Angela E , Sitch Alice J , Gilligan Lorna C , Vassiliadi Dimitra , Ambroziak Urszula , Lang Katharina , Kastelan Darko , Tabarin Antoine , Dennedy M Conall , Ueland Grethe Astrom , Quinkler Marcus , Masjkur Jimmy Rusdian , Fassnacht Martin , Ivovic Miomira , Terzolo Massimo , Beuschlein Felix , Manolopoulos Konstantinos , O'Reilly Michael W , Tsagarakis Stylianos , Shackleton Cedric H L , Deeks Jonathan J , Bancos Irina , Arlt Wiebke

Background: Benign adrenal tumours (AT) can be non-functioning (NFAT) or associated with cortisol excess, as indicated by failure to suppress serum morning cortisol to <50 nmol/l in the 1mg-dexamethasone suppression test (1 mg-DST). The latter group divides into patients with clinically overt signs of cortisol excess (adrenal Cushing’s syndrome, CUSH) and patients lacking CUSH signs (mild autonomous cortisol excess, MACE). Smaller series and a recent meta-analysis rep...

ea0065op6.4 | Neuroendocrinology, Pituitary and Neoplasia | SFEBES2019

Urine steroid metabolomics as a novel diagnostic tool for recurrent adrenocortical carcinoma detection

Chortis Vasileios , Nijman Thomas , Bancos Irina , Gilligan Lorna C , Taylor Angela E , Ronchi Cristina L , O'Reilly Michael W , Schreiner Jochen , Asia Miriam , Riester Anna , Terzolo Massimo , Libe Rosella , Quinkler Marcus , Canu Letizia , Paiva Isabel , Bugalho Maria J , Kastelan Darko , Dennedy M Conall , Sherlock Mark , Ambroziak Urszula , Vassiliadi Dimitra , Bertherat Jerome , Beuschlein Felix , Fassnacht Martin , Deeks Jonathan J , Biehl Michael , Arlt Wiebke

Objective: Urine steroid metabolomics, combining mass spectrometry-based steroid profiling and machine learning, has been described as a novel diagnostic tool for detection of adrenocortical carcinoma (ACC). This proof-of-concept study evaluated the performance of urine steroid metabolomics as a tool for post-operative recurrence detection after microscopically complete (R0) resection of ACC.Methods: 135 ACC patients from 14 clinical centres provided pos...